2025
The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study
Huelsboemer L, Hosseini H, Klimitz F, Diatta F, Boroumand S, O'Brien C, Parikh N, Stögner V, Formica R, Ko C, Azzi J, Draper E, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study. Journal Of Plastic Reconstructive & Aesthetic Surgery 2025, 103: 286-296. PMID: 40043533, DOI: 10.1016/j.bjps.2025.01.028.Peer-Reviewed Original ResearchDe novo donor-specific antibodiesDonor-specific antibodiesDonor-specific antibody positivityChronic rejectionC4d depositionGraft lossPrognostic relevanceRejection gradeGrades of acute cellular rejectionDonor-specific antibody statusOccurrence of chronic rejectionTime pointsFacial vascularized composite allotransplantationAcute rejection gradeAcute cellular rejectionTissue typing laboratoriesAcute rejection eventsRetrospective cohort studyTransplant-related outcomesFace transplant patientsVascularized composite allotransplantationCellular rejectionTransplant patientsC4d levelsRetrospective analysis
2020
Defining chronic rejection in vascularized composite allotransplantation—The American Society of Reconstructive Transplantation and International Society of Vascularized Composite Allotransplantation chronic rejection working group: 2018 American Society of Reconstructive Transplantation meeting report and white paper Research goals in defining chronic rejection in vascularized composite allotransplantation
Kaufman C, Kanitakis J, Weissenbacher A, Brandacher G, Mehra M, Amer H, Zelger B, Zelger B, Pomahac B, McDiarmid S, Cendales L, Morelon E. Defining chronic rejection in vascularized composite allotransplantation—The American Society of Reconstructive Transplantation and International Society of Vascularized Composite Allotransplantation chronic rejection working group: 2018 American Society of Reconstructive Transplantation meeting report and white paper Research goals in defining chronic rejection in vascularized composite allotransplantation. SAGE Open Medicine 2020, 8: 2050312120940421. PMID: 32704373, PMCID: PMC7361482, DOI: 10.1177/2050312120940421.Peer-Reviewed Original ResearchChronic rejectionComposite allograftsFunctional declineReconstructive transplantationComposite allotransplantationHistologic evidenceDe novo donor-specific antibodiesAmerican SocietyNovo donor-specific antibodiesNormal allograft functionDonor-specific antibodiesInternational SocietyVascularized Composite AllotransplantationAcute rejectionAllograft functionAllograft recipientsImmunosuppressive therapyTreatment regimensRisk factorsUterine transplantationUpper extremityMeeting reportAllograftsTransplantationClinical cases
2016
Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients
Borges T, O’Malley J, Wo L, Murakami N, Smith B, Azzi J, Tripathi S, Lane J, Bueno E, Clark R, Tullius S, Chandraker A, Lian C, Murphy G, Strom T, Pomahac B, Najafian N, Riella L. Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients. American Journal Of Transplantation 2016, 16: 2158-2171. PMID: 26749226, PMCID: PMC4979599, DOI: 10.1111/ajt.13705.Peer-Reviewed Original ResearchConceptsDe novo donor-specific antibody developmentDe novo donor-specific antibodiesInterleukin-17-producing T cellsT helper 2 cell phenotypeFacial transplantationDonor-specific antibody developmentNovo donor-specific antibodiesChemotactic protein-1 levelsPeripheral blood mononuclear cellsAcute cellular rejectionAnti-HLA antibodiesDonor-specific antibodiesFollicular helper cellsImmune cell subsetsProtein-1 levelsBlood mononuclear cellsMedium-term outcomesSkin biopsy specimensFull facial transplantationCellular rejection processLife-changing procedureCellular rejectionCodominant roleDonor alloreactivityTransplant recipients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply